Focusing on New Drugs and Other Products by Strengthening Sales Capabilities
First written in FY2016. 29 of 38 entries say "Restated". Latest entry: 2026-08-19.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Revenue from new drugs exceeded the previous fiscal year. Lialda, a treatment for ulcerative colitis; Goofice and Movicol, treatments for chronic constipation; Treprost, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Uric, a treatment for gout and hyperuricemia; and Omvoh, a treatment for ulcerative colitis and Crohn’s disease, all recorded growth.」
Full-year revenue from the major new-drug portfolio exceeded the previous fiscal year, with the company’s focus on new drugs reflected in growth across multiple products. - 2026-04-16AdvancedOther Disclosures
「We believe that this approval will enable us to address a broader range of treatment needs. Going forward, we will continue to provide appropriate information to healthcare professionals and contribute to improving patients' QOL.」
Shows that the indication range for the major new drug Onbo has been expanded and that its product value is being realized through information provision activities. - FY2026-H1AdvancedAnnual report
「Revenue from new drugs grew, including Lialda, a treatment for ulcerative colitis; Goofice and Movicol, treatments for chronic constipation; Treprost, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Uric, a treatment for gout and hyperuricemia; and Omvoh, a treatment for ulcerative colitis and Crohn’s disease.」
The company states that revenue from multiple major new drugs grew during the interim consolidated accounting period, demonstrating tangible progress in its focus on new drugs in terms of operating performance. - FY2025AdvancedAnnual report
「We will maximize the product value of 5 major new drugs and strengthen earnings power by expanding the pipeline through in-licensing.」
The former focus on new drugs was given concrete form through maximizing the value of the 5 major products Uric, Omvoh, Cortiment, Goofice, and Treprost, and expanding the pipeline through in-licensing. - FY2025-H1RestatedAnnual report
「Revenue from new drugs exceeded the same period of the previous year, driven by growth in Lialda, a treatment for ulcerative colitis; Goofice and Movicol, treatments for chronic constipation; Uric, a treatment for gout and hyperuricemia; and Treprost, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.」
The company continues to focus on new drugs in priority areas and states that revenue from multiple new drugs exceeded the same period of the previous year. - FY2024-Q3RestatedAnnual report
「To this end, we have made focused efforts to address the challenges of “maximizing revenue in priority areas centered on new drugs,” “investing in business activities that contribute to future competitiveness,” and “strengthening our corporate structure to drive innovation and improve productivity.”」
The company continues to identify the challenge of maximizing revenue centered on new drugs in priority areas, which gives concrete form to the former “focus on new drugs and other products.” - FY2024-Q2RestatedAnnual report
「“Maximizing revenue in priority areas centered on new drugs”」
The company continues to identify the challenge of maximizing revenue centered on new drugs in priority areas, which gives concrete form to the former “focus on new drugs and other products.” - FY2024-Q1RestatedAnnual report
「“Maximizing revenue in priority areas centered on new drugs”」
The company continues to identify the challenge of maximizing revenue centered on new drugs in priority areas, which gives concrete form to the former “focus on new drugs and other products.” - FY2023RestatedAnnual report
「Maximizing revenue in priority areas centered on new drugs」
The company continues to identify the former “focus on new drugs and other products” as maximizing revenue centered on new drugs in priority areas. - FY2023-Q3RestatedAnnual report
「To this end, we have made focused efforts to address the challenges of “maximizing revenue in priority areas centered on new drugs,” “investing in business activities that contribute to future competitiveness,” and “strengthening our corporate structure to drive innovation and improve productivity.”」
The company continues to identify the challenge of maximizing revenue centered on new drugs in priority areas, which gives concrete form to the former “focus on new drugs and other products.” - FY2023-Q2RestatedAnnual report
「“Maximizing revenue in priority areas centered on new drugs”」
The company continues to identify the priority challenge of maximizing revenue centered on new drugs in priority areas, which gives concrete form to the former “focus on new drugs and other products.” - FY2023-Q1ReframedAnnual report
「“Maximizing revenue in priority areas centered on new drugs”」
The former “focus on new drugs and other products” is expressed as the challenge of maximizing revenue centered on new drugs in priority areas. - FY2022RestatedAnnual report
「Under these circumstances, during the current consolidated fiscal year, our Group made focused efforts in line with its basic policy of prioritizing profits and continuing to invest for the future in order to respond to changes in the business environment and continue sustainable growth, including “focus on new drugs and other products,” “continued investment to build the next generation of core businesses,” and “strategic reallocation of resources through selection and concentration.”」
The company continued the 3 traditional priority measures, including a focus on new drugs and other products, during the current consolidated fiscal year. - FY2022-Q3RestatedAnnual report
「Against this backdrop, during the third quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The company continues to focus on new drugs and other products as a priority measure for the first 9 months of the current fiscal year. - FY2022-Q2RestatedAnnual report
「“Focus on new drugs and other products”」
The company continues to focus on new drugs and other products as a priority measure for the first six months of the current fiscal year. - FY2022-Q1RestatedAnnual report
「We have focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus."」
The company continues to focus on new drugs and other products as a priority measure for the first quarter of the current fiscal year. The simplified wording derived from the former “focus on new drugs and other products through stronger sales capabilities” continues to be used. - FY2021RestatedAnnual report
「• Focus on new drugs and other products」
The 21–23 Medium-Term Management Plan also continues to identify a focus on new drugs and other products as a priority measure. - FY2021-Q3RestatedAnnual report
「We have focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus."」
The company continues to focus on new drugs and other products as a priority measure for the first 9 months of the current fiscal year. The simplified wording derived from the former “focus on new drugs and other products through stronger sales capabilities” has also been retained. - FY2021-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The company continues to identify the simplified expression, “focus on new drugs and other products,” derived from the former “focus on new drugs and other products through stronger sales capabilities,” as a priority measure. - FY2021-Q1RestatedAnnual report
「“Focus on new drugs and other products”」
The company continues to use the simplified wording from the former “focus on new drugs and other products through stronger sales capabilities,” and no material change in its policy of focusing on new drugs and other products is described. - FY2020ReframedAnnual report
「• Focus on new drugs and other products」
In the priority measures of the 20–22 Medium-Term Management Plan, the wording has been simplified from “focus on new drugs and other products through stronger sales capabilities” to “focus on new drugs and other products.” The former wording is still used in the explanation of operating results. - FY2020-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2019 through fiscal 2021 announced on 1 April 2019, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The company continues to focus on new drugs and other products through stronger sales capabilities as a priority measure in the Medium-Term Management Plan for fiscal 2019–fiscal 2021. - FY2020-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products by strengthening sales capabilities," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The company continues to focus on new drugs and other products through stronger sales capabilities as a priority measure for the first six months of the fiscal year. - FY2020-Q1RestatedAnnual report
「Focusing on New Drugs and Other Products by Strengthening Sales Capabilities」
It continued as a key initiative under the medium-term management plan for fiscal 2019 through fiscal 2021. - FY2019RestatedAnnual report
「The policy of the Group's 3-year medium-term management plan (the "19-21 Medium-Term Management Plan") is to "bring together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure to respond to further changes in the business environment," and we will continue to focus on the following 3 areas so that we can respond to changes in the business environment: concentrating on new drugs and other products by strengthening sales capabilities, continued investment to build the next generation of core businesses, and the strategic reallocation of resources through selective focus.」
The 19–21 Medium-Term Management Plan also continues to identify a focus on new drugs and other products through stronger sales capabilities as a priority measure. - FY2019-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2018 through fiscal 2020 announced on 2 April 2018, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The company continues to focus on new drugs and other products through stronger sales capabilities as a priority measure in the Medium-Term Management Plan for fiscal 2018–fiscal 2020. - FY2019-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products by strengthening sales capabilities," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The company continues to focus on new drugs and other products through stronger sales capabilities as a priority measure for the first six months of the current fiscal year. - FY2019-Q1RestatedAnnual report
「Focusing on New Drugs and Other Products by Strengthening Sales Capabilities」
It continues to be presented as a key initiative under the medium-term management plan for fiscal 2018 through fiscal 2020. - FY2018RestatedAnnual report
「Focusing on New Drugs and Other Products by Strengthening Sales Capabilities」
It continues to be presented as one of the key initiatives under the 18-20 Medium-Term Management Plan. - FY2018-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The company continues to identify a focus on new drugs and other products through stronger sales capabilities as a priority measure in the Medium-Term Management Plan. - FY2018-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The company continues to identify a focus on new drugs and other products through stronger sales capabilities as a priority measure in the new Medium-Term Management Plan. - FY2018-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The new Medium-Term Management Plan also identifies a focus on new drugs and other products through stronger sales capabilities as a priority measure. - FY2017-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The company has reaffirmed its focus on new drugs and other products through stronger sales capabilities as a priority measure in the Medium-Term Management Plan. - FY2017-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The company has reaffirmed its focus on new drugs and other products through stronger sales capabilities as a priority measure in the Medium-Term Management Plan. - FY2017-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The company has reiterated its focus on new drugs and other products through stronger sales capabilities as a priority measure in the Medium-Term Management Plan. - FY2016First statedAnnual report
「Focusing on New Drugs and Other Products by Strengthening Sales Capabilities」
It was identified as a priority measure in the Medium-Term Management Plan.